Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130667 | 0.83 | PIP4K2A (0.38) | EGFRRIPK2PIP4K2APIP4K2CAURKB | |
| SCHEMBL7117284 | 0.83 | JUN (0.38) | EGFRRIPK2PIP4K2APIP4K2CAURKB | |
| SCHEMBL7129801 | 0.75 | RIPK2 (0.48) | EGFRRIPK2AURKBHTTRIPK3 | |
| SCHEMBL7115900 | 0.72 | ABL1 (0.38) | NR2E1MAPK13 | |
| SCHEMBL7122204 | 0.69 | DYRK1A (0.40) | NR2E1EGFRMAPK13HIF1A | |
| Hydrochloric Acid SCHEMBL7123978 | 0.69 | DYRK1A (0.40) | NR2E1EGFRMAPK13HTTHIF1A | |
| Hydrochloric Acid SCHEMBL7117269 | 0.69 | DYRK1A (0.40) | NR2E1EGFRMAPK13HTTHIF1A | |
| SCHEMBL7126625 | 0.67 | EGFR (0.37) | EGFRPIP4K2APIP4K2CHTTHIF1A | |
| SCHEMBL7118546 | 0.66 | L3MBTL1 (0.37) | EGFRRIPK2PIP4K2APIP4K2CAURKB | |
| SCHEMBL7128444 | 0.66 | PDE4A (0.40) | RIPK2HTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | NR2E1 326/4885EGFR 319/4885RIPK2 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.